LFA
JAZZ icon

LGT Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

LGT Financial Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$106 – 522
2025
Q2 		$106 Buy
+1
New +$109 ﹤0.01% 591
2023
Q4 		– Sell
-87
Closed -$11.3K – 920
2023
Q3 		$11.3K Buy
+87
New +$11.6K 0.01% 458

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

LGT Financial Advisors's JAZZ Position: Q3 2025 in Review

LGT Financial Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 1 share — an estimated $106 sold.

LGT Financial Advisors first reported a position in JAZZ in Q3 2023 and held it in 2 quarters. The position peaked at $11.3K in Q3 2023. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

  • LGT Financial Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 1 Jazz Pharmaceuticals share in Q3 2025, an estimated $106.
  • LGT Financial Advisors first reported a position in Jazz Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • LGT Financial Advisors's Jazz Pharmaceuticals position peaked at $11.3K in Q3 2023.
  • 503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on LGT Financial Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.